#OncClub
LightNews LightNews
cancerassassin1.bsky.social
Thank you @onclive.bsky.social for this thorough review of our recent clinical trial for patients with metastatic GI cancers. Looking forward to more #GICancer #OncClub discussions to follow over the next few days at #ASCO25!
@thelancetoncol.bsky.social: www.sciencedirect.com/science/arti...
May 29, 2025 at 8:19 PM
onclive.bsky.social
Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors
#GICancer @cancerassassin1.bsky.social #OncClub
www.onclive.com/view/neoanti...
www.onclive.com
May 29, 2025 at 8:04 PM
onclive.bsky.social
Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML #OncClub #leusm #oncology www.onclive.com/view/venetoc...
Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML
Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.
www.onclive.com
January 27, 2025 at 8:30 PM
onclive.bsky.social
Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma @upmcnews.bsky.social #OncClub #sarcoma www.onclive.com/view/pembrol...
Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma
The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.
www.onclive.com
January 18, 2025 at 2:51 PM
onclive.bsky.social
IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML #mpnsm #leusm #oncology #OncClub www.onclive.com/view/ihc-tes...
IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations MDS and AML.
www.onclive.com
July 24, 2025 at 2:36 PM
onclive.bsky.social
In an indirect comparative analysis of the phase 3 SEQUOIA and AMPLIFY trials, zanubrutinib was associated with improved PFS vs acalabrutinib plus venetoclax in treatment-naive CLL.

Read more @fredhutch.org #leusm #oncology #OncClub www.onclive.com/view/indirec...
Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL | OncLive
In a post hoc indirect comparison, data showed zanubrutinib was linked with improved PFS vs acalabrutinib/venetoclax in treatment-naive CLL.
www.onclive.com
April 1, 2026 at 12:50 PM
onclive.bsky.social
Fixed-duration therapies have transformed the CLL treatment landscape, but improving outcomes for high-risk patients through continued research and novel drug development remains crucial #OncClub www.onclive.com/view/improve...
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens | OncLive
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
onclive.com
July 17, 2026 at 7:16 PM
onclive.bsky.social
WATCH👀: Daniel Ermann, MD, breaks down findings from a real-world study retrospectively examining outcomes with zanubrutinib vs acalabrutinib in treatment-naive CLL #OncClub #leusm #oncology www.onclive.com/view/dr-erma...
Dr Ermann on BTK Inhibitor Selection in Treatment-Naive CLL | OncLive
Daniel Ermann, MD, discusses improvements shown in real-world data for zanubrutinib compared with acalabrutinib in treatment-naive CLL.
www.onclive.com
July 15, 2026 at 8:04 PM
onclive.bsky.social
📢 @ascocancer.bsky.social #ASCO26: HERIZON-GEA-01 subgroup data show zanidatamab + tislelizumab + chemotherapy improved PFS and OS vs trastuzumab + chemotherapy in HER2+ gastroesophageal adenocarcinoma—regardless of PD-L1 status. #OncClub

Learn more: www.onclive.com/view/herizon...
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA | OncLive
Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.
www.onclive.com
June 3, 2026 at 1:14 AM
onclive.bsky.social
Retrospective data show up-front dose reductions of enfortumab vedotin lowered the risk of treatment interruptions without impeding OS in patients with advanced urothelial cancer receiving first-line enfortumab vedotin plus pembrolizumab #blcsm #oncology #OncClub www.onclive.com/view/enfortu...
www.onclive.com
February 4, 2026 at 10:12 PM
onclive.bsky.social
WATCH: Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer. @nufeinbergmed.bsky.social @jamanetworkopen.com #OncClub #oncology
www.onclive.com/view/dr-shah...
Dr Shah on Disease-Related Exacerbation With ICIs in Patients With Cancer and Preexisting NAIDs
Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.
www.onclive.com
August 4, 2025 at 2:13 PM
onclive.bsky.social
Skipping Surgery in Early HER2+ Breast Cancer or TNBC? Phase 2 Trial Data Highlight Feasibility of Selective Omission @mdanderson.bsky.social #bcsm #oncology #OncClub www.onclive.com/view/skippin...
June 24, 2025 at 2:10 PM